Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nasal discomfort22.12.03.0120.001236%Not Available
Musculoskeletal discomfort15.03.04.0010.000354%Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Vascular occlusion24.04.02.0150.000091%Not Available
Free prostate-specific antigen increased13.23.01.001--Not Available
Affect lability19.04.01.001--Not Available
Injection site discomfort12.07.03.019; 08.02.03.018--Not Available
Transaminases increased13.03.04.036--Not Available
Cerebral disorder17.02.10.0170.000182%Not Available
Prostate examination abnormal13.15.01.026--Not Available
Haemorrhage24.07.01.002--Not Available
Haemorrhage urinary tract24.07.01.007; 20.02.03.005--Not Available
Pulmonary mass22.02.07.0040.000382%Not Available
Muscle mass15.05.03.0180.000200%Not Available
Prostate induration21.04.01.006--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Testis cancer21.13.02.001; 16.25.03.0010.000227%Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Precocious puberty21.03.02.009; 05.05.03.0010.000827%
Hypogonadism21.03.02.010; 05.05.04.0020.000382%Not Available
Vasodilation procedure25.03.01.001--Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.003--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.001390%Not Available
Angiopathy24.03.02.0070.000682%Not Available
Epidermal necrosis23.03.03.035--Not Available
Urine output increased13.13.03.002--Not Available
Induration08.01.03.020--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Ischaemic cerebral infarction24.04.06.013; 17.08.01.0220.000273%Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 19 Pages